Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Cree, Bruce A C, Bennett, Jeffrey L, Kim, Ho Jin, Weinshenker, Brian G, Pittock, Sean J, Wingerchuk, Dean M, Fujihara, Kazuo, Paul, Friedemann, Cutter, Gary R, Marignier, Romain, Green, Ari J, Aktas,Language:
english
Journal:
The Lancet
DOI:
10.1016/S0140-6736(19)31817-3
Date:
September, 2019
File:
PDF, 391 KB
english, 2019